Want to see BRKR full AI Analyst Report?
Operating Income by Segment
Shows profit contribution from each business unit, revealing which segments deliver healthy margins and which are weighing on earnings. Helps identify whether revenue growth is translating into sustainable profitability and where management is focusing cost control or investment efforts.Profitability has concentrated in the BSI businesses (BioSpin and CALID) while the Life Science line has effectively disappeared from segment income (a reclassification/divestiture issue), so operating leverage now sits with BSI. The dominant volatility driver is large, erratic ‘Unallocated Expenses’—including one‑time lease impairment/restructuring hits called out in Q1—which can mask underlying segment momentum. Management’s strong BSI bookings, multi‑year BEST orders and ~$140M of cost savings support the reconfirmed FY26 margin recovery, but persistent unallocated charges are the main execution risk to watch.
Date | Unallocated Expenses | Corporate & Other | BSI BioSpin | BSI CALID | BSI Life Science | BSI NANO | BEST |
|---|---|---|---|---|---|---|---|
Jun 30, 2026 | -$183.90M | -$32.80M | $41.70M | $72.30M | $0.00 | $29.80M | $7.60M |
Mar 31, 2026 | -$74.10M | -$29.10M | $28.80M | $62.60M | $0.00 | $14.40M | $7.60M |
Dec 31, 2025 | -$77.20M | -$31.90M | $63.00M | $71.80M | $0.00 | $45.10M | $5.50M |
Sep 30, 2025 | -$157.60M | -$34.00M | $33.30M | $76.00M | $0.00 | $23.50M | $7.00M |
Jun 30, 2025 | -$60.00M | -$21.10M | $23.10M | $53.30M | $0.00 | $9.40M | $7.20M |
Mar 31, 2025 | -$70.00M | -$26.90M | $37.10M | $61.50M | $0.00 | $23.10M | $7.00M |
Dec 31, 2024 | -$105.70M | -$31.70M | $78.60M | $78.00M | $0.00 | $44.30M | $8.60M |
Sep 30, 2024 | -$61.00M | -$24.70M | $56.80M | $58.70M | $0.00 | $30.60M | $7.70M |
Jun 30, 2024 | -$62.40M | -$24.30M | $46.60M | $58.40M | $0.00 | $19.20M | $10.60M |
Mar 31, 2024 | -$35.80M | -$23.10M | $34.60M | $51.10M | $0.00 | $29.80M | $8.20M |